Intelligence · Patents
Patents expiring in 2035
Annual patent cliff calendar for 2035 — US pharmaceutical patents by expiration date.
- Patents
- 1,447
Quick answer
1,447 indexed pharmaceutical patents have expiration dates in 2035. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 9157916
Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays
granted -
US 9163022
Tricyclic compounds as modulators of TNF-α synthesis and as PDE4 inhibitors
granted -
US 9163271
Methods and compositions for the production of orthogonal tRNA-aminoacyl tRNA synthetase pairs
granted -
US 9163245
Compositions for linking zinc finger modules
granted -
US 9163235
Inhibitors of the miR-15 family of micro-RNAs
granted -
US 9163085
Anti-OX40 antibodies and methods of treating cancer
granted -
US 9163215
Generation of lineage-restricted progenitor cells from differentiated cells
granted -
US 9163244
Suppressors of CpG oligonucleotides and methods of use
granted -
US 9163236
Pharmaceutical composition comprising NANOG SHRNA, and method of using NANOG SHRNA to treat cancer
granted -
US 9163248
Targeting pseudotyped retroviral vectors
granted -
US 9163042
Prodrugs of pyridone amides useful as modulators of sodium channels
granted -
US 9162968
Cyclohexane-1,3-diones for use in the treatment of amyotrophic lateral sclerosis
granted -
US 9161735
Systems, compositions, and methods for local imaging and treatment of pain
granted -
US 9162982
4-[2-(2-fluorophenoxy methyl)phenyl]piperidine compounds
granted -
US 9161984
Formulations and methods of use for alpha connexin C-terminal (ACT) peptides
granted -
US 9161936
Laquinimod for treatment of GABA mediated disorders
granted -
US 9161995
Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (CFTR) gene
granted -
US 9161948
Peptide oligonucleotide conjugates
granted -
US 9161935
Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNF therapy
granted -
US 9161969
Protection against influenza infection by granulocyte-macrophage colony stimulating factor
granted -
US 9161990
Hydrochloride salts of a glycopeptide-cephalosporin antbiotic compond
granted -
US 9162980
Anti-depression compounds
granted -
US 9163068
Influenza virus recombinant proteins
granted -
US 9163258
Method for the treatment of obesity
granted -
US 9162989
2,4-Pyrimidinediamine compounds and their uses
granted -
US 9169326
Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
granted -
US 9169238
Solid pharmaceutical composition
granted -
US 9168262
Estriol therapy for multiple sclerosis and other autoimmune diseases
granted -
US 9169297
Subgenomic replicons of the flavivirus dengue
granted -
US 9167841
Tangerine peel extract and its preparation and application
granted -
US 9169509
Topoisomerase 2b as a predictor of susceptibility to anthracycline-induced cardiotoxicity
granted -
US 9168266
Hybrid diazeniumdiolated compounds, pharmaceutical compositions, and method of treating cancer
granted -
US 9168227
Multi-encapsulated microspheres made with oxidized cellulose for in-situ reactions
granted -
US 9168261
Compositions and methods for cartilage repair
granted -
US 9168269
Inhibitors of long and very long chain fatty acid metabolism as broad spectrum anti-virals
granted -
US 9168291
β-mannosylceramide and stimulation of NKT cell anti-tumor immunity
granted -
US 9169296
Expression and assembly of human group C rotavirus-like particles and uses thereof
granted -
US 9169350
N-maleimidyl polymer derivatives
granted -
US 9169495
Targeted gene delivery to non-phagocytic mammalian cells via bacterially derived intact minicells
granted -
US 9169280
Methods for the synthesis of plasmalogens and plasmalogen derivatives, and therapeutic uses thereof
granted -
US 9168311
Oligomer-dantrolene conjugates and related compounds
granted -
US 9168297
Regulation of skin pigmentation by neuregulin-1 (NRG-1)
granted -
US 9169354
Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
granted -
US 9169321
Activatable binding polypeptides and methods of identification and use thereof
granted -
US 9169313
Method of treatment of cancers characterized by ligand-dependent activating mutations in FGFR2 with FGFR1 ECD proteins
granted -
US 9169303
Vault compositions for immunization
granted -
US 9169294
Anti-angiogenic molecules, nanostructures and uses thereof
granted -
US 9169249
Protein kinase C inhibitors and uses thereof
granted
Frequently asked questions
How many pharma patents expire in 2035?
1,447 published patents in our USPTO index have expiration dates falling in calendar year 2035.